News & Media

Press release 2014/12/22

MIV-802 has been selected as a candidate drug and enters non-clinical development for the treatment of hepatitis C infection

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) announced that MIV-802 has been selected as a candidate drug (CD) from its...

Read more

Press release 2014/11/20

Resolutions at the extraordinary general meeting in Medivir on 20 November 2014

Voluntary redemption programmeThe extraordinary general meeting in Medivir Aktiebolag (publ) on 20 November 2014 resolved, in accordance with the board of...

Read more

Press release 2014/11/20

Interim Report, January – September 2014

Financial summary for the third quarter* July to September 2014 (2013) Net turnover totalled SEK 617.8 million (SEK 80.2 m), SEK...

Read more

Press release 2014/11/06

Olysio® gains additional FDA approval as all-oral treatment in combination with sofosbuvir for treatment of hepatitis C infection

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm:MVIR) announces that the U.S. Food and Drug Administration (FDA) has approved Olysio® (simeprevir) in...

Read more

Press release 2014/10/30

Medivir and county councils conclude agreement on Olysio®-based treatment for hepatitis C

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company has entered into an agreement with Swedish county councils regarding...

Read more

Press release 2014/10/28

Medivir Nomination Committee appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced that its Nomination Committee has been appointed. According to an AGM resolution,...

Read more

Press release 2014/10/23

Notice of extraordinary general meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the extraordinary general meeting on Thursday 20 November 2014 at 10 a.m....

Read more

Press release 2014/10/16

Optimization of capital structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces the intention of launching a voluntary share redemption program. “The successful market...

Read more

Press release 2014/10/14

Stable sales for OLYSIO during the third quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 796...

Read more

Press release 2014/10/10

Phase II IMPACT study initiated to evaluate Simeprevir in combination with Sofosbuvir and Daclatasvir to treat genotype 1 and 4 hepatitis C patients

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that its partner Janssen recently initiated patient enrolment in a phase II...

Read more

Press release 2014/10/09

Medivir to present data from its Cathepsin S inhibitor program including MIV-247 for neuropathic pain, at the 15th World Congress on Pain

Stockholm, Sweden – Medivir AB (OMX:MVIR) announces that data from its cathepsin S inhibitor drug development program for neuropathic pain will...

Read more

Press release 2014/10/07

Medivir Capital Markets Meeting on 16 October 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that a Capital Markets Meeting will be arranged for investors, analysts and...

Read more